New CEO Jake Leach said the company plans a trial readout in mid-2026 to support coverage of its glucose sensors in Type 2 users who don’t take insulin.
Medical device company DexCom (NASDAQ:DXCM) reported Q4 CY2025 results beating Wall Street’s revenue expectations, with sales up 13.1% year on year to $1.26 billion. The company expects the full ...
Q4 2025 Earnings Call February 12, 2026 4:30 PM ESTCompany ParticipantsSean Christensen - Vice President of Finance and ...
19hon MSN
Dexcom outlines 2026 revenue growth of 11%-13% with G7 15 day rollout and international expansion
Q4 2025 Management View Jacob Leach, President, CEO & Director, marked his first call as CEO by outlining three strategic ...
Zacks Investment Research on MSN
Dexcom stock falls despite Q4 earnings beat, G7 rollout drives growth
DexCom, Inc. DXCM reported fourth-quarter 2025 adjusted earnings per share (EPS) of 68 cents, which beat the Zacks Consensus ...
Churchill Capital Corp X ("Churchill X") , a publicly traded special purpose acquisition company, today announced that its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results